The health and economic burden of osteoporotic fractures in Singapore and the potential impact of increasing treatment rates through more pharmacological options
- 16 Downloads
This study aims to estimate the health and economic burden of osteoporosis in Singapore from 2017 to 2035, and to quantify the impact of increasing the treatment rate of osteoporosis.
Population forecast data of women and men aged 50 and above in Singapore from 2017 to 2035 was used along with prevalence rates of osteoporosis to project the osteoporosis population over time. The population projections by sex and age group were used along with osteoporotic fracture incidence rates by fracture type (hip, vertebral, other), and average direct and indirect costs per case to forecast the number of fractures, the total direct health care costs, and the total indirect costs due to fractures in Singapore. Data on treatment rates and effects were used to model the health and economic impact of increasing treatment rate of osteoporosis, using different hypothetical levels.
Between 2017 and 2035, the incidence of osteoporotic fractures is projected to increase from 15,267 to 24,104 (a 57.9% increase) F 10,717 to 17,225 (a 60.7% increase) and M 4550 to 6878 (a 51.2% increase). The total economic burden (including direct costs and indirect costs to society) associated with these fractures is estimated at S$183.5 million in 2017 and is forecasted to grow to S$289.6 million by 2035. However, increasing the treatment rate for osteoporosis could avert up to 29,096 fractures over the forecast period (2017–2035), generating cumulative total cost savings of up to S$330.6 million.
Efforts to improve the detection, diagnosis, and treatment of osteoporosis are necessary to reduce the growing clinical, economic, and societal burden of fractures in Singapore.
KeywordsOsteoporosis Osteoporotic fractures Economic burden Asia Singapore Health burden
This study was funded by Amgen Inc.
Compliance with ethical standards
Conflict of interest
Manju Chandran, Tang Ching Lau, Isabelle Gagnon-Arpin, Alexandru Dobrescu, and Wenshan Li have no conflict of interest. Mallory Leung, Narendra Patil, and Zhongyun Zhao hold Amgen stock and are employees of Amgen.
- 1.International Osteoporosis Foundation (2013) Asia-Pacific Audit: SingaporeGoogle Scholar
- 2.Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA, IOF EURPo (2013) Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos 8:137. https://doi.org/10.1007/s11657-013-0137-0 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Yung CK, Fook-Chong S, Chandran M (2012) The prevalence of recognized contributors to secondary osteoporosis in South East Asian men and post-menopausal women. Are Z score diagnostic thresholds useful predictors of their presence? Arch Osteoporos 7:49–56. https://doi.org/10.1007/s11657-012-0078-z CrossRefPubMedGoogle Scholar
- 4.Cheung C-L, Ang SB, Chadha M, Chow ES-L, Chung Y-S, Hew FL, Jaisamrarn U, Ng H, Takeuchi Y, Wu C-H, Xia W, Yu J, Fujiwara S (2018) An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study. Osteoporosis Sarcopenia 4(1):16–21. https://doi.org/10.1016/j.afos.2018.03.003 CrossRefPubMedGoogle Scholar
- 8.International Osteoporosis Foundation (2009) The Asian audit epidemiology, costs and burden of osteoporosis in Asia 2009. SwitzerlandGoogle Scholar
- 15.Lee AY, Chua BS, Howe TS (2007) One-year outcome of hip fracture patients admitted to a Singapore hospital: quality of life post-treatment. Singap Med J 48(11):996–999Google Scholar
- 16.Kung AW, Fan T, Xu L, Xia WB, Park IH, Kim HS, Chan SP, Lee JK, Koh L, Soong YK, Soontrapa S, Songpatanasilp T, Turajane T, Yates M, Sen S (2013) Factors influencing diagnosis and treatment of osteoporosis after a fragility fracture among postmenopausal women in Asian countries: a retrospective study. BMC Womens Health 13:7. https://doi.org/10.1186/1472-6874-13-7 CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Department of Statistics S (2017) Popul Trends 2017. https://www.singstat.gov.sg/publications/population-trends. Accessed February 9 2018
- 19.Lee J, Lee S, Jang S, Ryu OH (2013) Age-related changes in the prevalence of osteoporosis according to gender and skeletal site: the Korea National Health and Nutrition Examination Survey 2008-2010. Endocrinol Metab (Seoul) 28(3):180–191. https://doi.org/10.3803/EnM.2013.28.3.180 CrossRefGoogle Scholar
- 23.Watts JJ, Abimanyi-Ochom, J., Sanders, K.M. Osteoporosis costing all Australians - a new burden of disease analysis - 2012 to 2022Google Scholar
- 25.Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 1:CD001155. https://doi.org/10.1002/14651858.CD001155.pub2 CrossRefGoogle Scholar
- 28.Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, Trial HPF (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822. https://doi.org/10.1056/NEJMoa067312 CrossRefGoogle Scholar
- 34.International Osteoporosis Foundation (2005) The adherence gap: why osteoporosis patients don’t continue with treatmentGoogle Scholar
- 36.Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, Borenstein J, Kendler DL, Investigators D (2012) Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23(1):317–326. https://doi.org/10.1007/s00198-011-1780-1 CrossRefPubMedGoogle Scholar
- 37.Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, Trial F (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. https://doi.org/10.1056/NEJMoa0809493 CrossRefPubMedPubMedCentralGoogle Scholar
- 40.Pongchaiyakul C, Nguyen ND, Jones G, Center JR, Eisman JA, Nguyen TV (2005) Asymptomatic vertebral deformity as a major risk factor for subsequent fractures and mortality: a long-term prospective study. J Bone Miner Res 20(8):1349–1355. https://doi.org/10.1359/JBMR.050317 CrossRefPubMedGoogle Scholar